
Quest Diagnostics Incorporated DGX
$ 196.12
1.27%
Quarterly report 2026-Q1
added 04-22-2026
Quest Diagnostics Incorporated Accounts Payables 2011-2026 | DGX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Quest Diagnostics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 307 M | 287 M | 378 M | 324 M | 357 M | 446 M | 263 M | 222 M | 224 M | 261 M | 279 M | 257 M | 258 M | 204 M | 215 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 446 M | 204 M | 285 M |
Quarterly Accounts Payables Quest Diagnostics Incorporated
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 357 M | - | - | - | 446 M | - | - | - | 263 M | - | - | - | 222 M | - | - | - | 224 M | - | - | - | 231 M | - | - | - | 279 M | - | - | - | 257 M | - | - | - | 258 M | - | - | - | 204 M | - | - | - | 215 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 446 M | 204 M | 269 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
Fulgent Genetics
FLGT
|
18.7 M | $ 19.5 | 7.5 % | $ 600 M | ||
|
Celcuity
CELC
|
6.41 M | $ 92.47 | 3.96 % | $ 4.32 B | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
1.88 M | $ 5.76 | 11.41 % | $ 7.66 M | ||
|
Castle Biosciences
CSTL
|
18.7 M | $ 21.6 | 5.93 % | $ 626 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
4.84 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
54.4 M | $ 133.06 | 4.75 % | $ 16.7 B | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
ICON Public Limited Company
ICLR
|
192 M | $ 152.8 | 6.18 % | $ 12 B | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 23.12 | 3.63 % | $ 1.23 B | ||
|
Illumina
ILMN
|
240 M | $ 168.06 | -1.68 % | $ 26 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
790 K | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
983 K | $ 1.79 | 2.29 % | $ 7.92 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Mettler-Toledo International
MTD
|
267 M | - | - | $ 24.3 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
42.9 M | - | - | $ 6.94 B | ||
|
NeoGenomics
NEO
|
23.1 M | $ 11.31 | 11.54 % | $ 1.45 B | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 185.79 | 3.29 % | $ 9.21 B | ||
|
Natera
NTRA
|
33.2 M | $ 222.1 | 4.84 % | $ 30.4 B | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 458.69 | 1.75 % | $ 13.2 B | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 19.75 | 3.73 % | $ 442 M | ||
|
Myriad Genetics
MYGN
|
30 M | $ 4.69 | 6.59 % | $ 434 M | ||
|
Personalis
PSNL
|
13 M | $ 12.1 | 12.24 % | $ 1.08 B | ||
|
Senseonics Holdings
SENS
|
4.06 M | $ 7.01 | 4.32 % | $ 293 M | ||
|
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
12.4 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
295 K | - | - | $ 4.94 M | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 260.97 | 0.79 % | $ 21.7 B | ||
|
Twist Bioscience Corporation
TWST
|
11.1 M | - | - | $ 4.42 B | ||
|
Thermo Fisher Scientific
TMO
|
3.62 B | $ 482.03 | 1.7 % | $ 182 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.12 | 3.52 % | $ 1.98 B | ||
|
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | ||
|
Waters Corporation
WAT
|
104 M | $ 376.47 | -0.87 % | $ 22.4 B |